{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.0","upperLimit":"27.1","value":"20.2"},{"groupId":"OG001","lowerLimit":"13.7","upperLimit":"35.3","value":"18.7"},{"groupId":"OG002","lowerLimit":"17.5","upperLimit":"36.5","value":"25.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"description":"OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"OG001","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From the date of randomization until date of death due to any cause (up to approximately 7 years)","title":"Part C (Randomized): Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}